We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Tango Therapeutics Inc (TNGX) USD0.0001

Sell:$3.00 Buy:$3.20 Change: $0.16 (5.44%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$3.00
Buy:$3.20
Change: $0.16 (5.44%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$3.00
Buy:$3.20
Change: $0.16 (5.44%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).

Contact details

Address:
201 Brookline Avenue, Suite 901
BOSTON
02215
United States
Telephone:
+1 (857) 3204900
Website:
https://www.tangotx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TNGX
ISIN:
US87583X1090
Market cap:
$299.70 million
Shares in issue:
107.42 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Barbara Weber
    President, Chief Executive Officer, Director
  • Daniella Beckman
    Chief Financial Officer
  • Adam Crystal
    President - Research and Development
  • Julie Carretero
    Chief Human Resource Officer
  • Douglas Barry
    Chief Legal Officer, Chief Compliance Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.